Nancy K Leidy1, Lindsey T Murray2, Brigitta U Monz3, Linda Nelsen4, Mitchell Goldman5, Paul W Jones6, Elizabeth J Dansie7, Sanjay Sethi8. 1. Evidera, 7101 Wisconsin Ave, Suite 1400, Bethesda, MD, 20814, USA. nancy.leidy@evidera.com. 2. Evidera, 7101 Wisconsin Ave, Suite 1400, Bethesda, MD, 20814, USA. lindsey.murray@evidera.com. 3. Formerly Boehringer Ingelheim GmbH, Ingelheim, Germany. lbmonz@t-online.de. 4. Merck, Sharp & Dohme, Corp, Whitehouse Station, NJ, USA. linda.m.nelsen@gsk.com. 5. AstraZeneca, Wilmington, DE, USA. mitchell.goldman@astrazeneca.com. 6. St. George's, University of London, London, UK. pjones@sgul.ac.uk. 7. Evidera, 7101 Wisconsin Ave, Suite 1400, Bethesda, MD, 20814, USA. elizabeth.dansie@evidera.com. 8. University of Buffalo, Buffalo, NY, USA. ssethi@buffalo.edu.
Abstract
BACKGROUND:Symptomatic relief is an important treatment goal for patients with COPD. To date, no diary for evaluating respiratory symptoms in clinical trials has been developed and scientifically-validated according to FDA and EMA guidelines. The EXACT - Respiratory Symptoms (E-RS) scale is a patient-reported outcome (PRO) measure designed to address this need. The E-RS utilizes 11 respiratory symptom items from the existing and validated 14-item EXACT, which measures symptoms of exacerbation. The E-RS total score quantifies respiratory symptom severity, and 3 domains assess breathlessness, cough and sputum, and chest symptoms. METHODS: This study examined the performance of the E-RS in each of 3 controlled trials with common and unique validation variables: one 6-month (N = 235, US) and two 3-month (N = 749; N = 597; international). Subjects completed the E-RS as part of a daily eDiary. Tests of reliability, validity, and responsiveness were conducted in each dataset. RESULTS: In each study, RS-Total score was internally consistent (Cronbach α) (0.88, 0.92, 0.92) and reproducible (intra-class correlation) in stable patients (2 days apart: 0.91; 7 days apart: 0.71, 0.74). RS-Total scores correlated significantly with the following criterion variables (Spearman's rho; p < 0.01, all comparisons listed here): FEV1% predicted (-0.19, -0.14, -0.15); St. George's Respiratory Questionnaire (SGRQ) (0.65, 0.52, 0.51); Breathlessness, Cough, and Sputum Scale (BCSS) (0.89, 0.89); modified Medical Research Council dyspnoea scale (mMRC) (0.40); rescue medication use (0.43, 0.42); Functional Performance Inventory Short-Form (FPI-SF) (0.43); 6-minute walk distance (6-MWT) (-0.30, -0.14) and incremental shuttle walk (ISWT) (-0.18) tests. Correlations between these variables and RS-Breathlessness, RS-Cough and Sputum, RS-Chest Symptoms scores supported subscale validity. RS-Total, RS-Breathlessness, and RS-Chest Symptoms differentiated mMRC levels of breathlessness severity (p < 0.0001). RS-Total and domain scores differentiated subjects with no rescue medication use and 3 or more puffs (p < 0.0001). Sensitivity to changes in health status (SGRQ), symptoms (BCSS), and exercise capacity (6MWT, ISWT) were also shown and responder definitions using criterion- and distribution-based methods are proposed. CONCLUSIONS: Results suggest the E-RS is a reliable, valid, and responsive measure of respiratory symptoms of COPD suitable for use in natural history studies and clinical trials. TRIAL REGISTRATION: MPEX: NCT00739648 ; AZ1: NCT00949975 ; AZ 2: NCT01023516.
RCT Entities:
BACKGROUND: Symptomatic relief is an important treatment goal for patients with COPD. To date, no diary for evaluating respiratory symptoms in clinical trials has been developed and scientifically-validated according to FDA and EMA guidelines. The EXACT - Respiratory Symptoms (E-RS) scale is a patient-reported outcome (PRO) measure designed to address this need. The E-RS utilizes 11 respiratory symptom items from the existing and validated 14-item EXACT, which measures symptoms of exacerbation. The E-RS total score quantifies respiratory symptom severity, and 3 domains assess breathlessness, cough and sputum, and chest symptoms. METHODS: This study examined the performance of the E-RS in each of 3 controlled trials with common and unique validation variables: one 6-month (N = 235, US) and two 3-month (N = 749; N = 597; international). Subjects completed the E-RS as part of a daily eDiary. Tests of reliability, validity, and responsiveness were conducted in each dataset. RESULTS: In each study, RS-Total score was internally consistent (Cronbach α) (0.88, 0.92, 0.92) and reproducible (intra-class correlation) in stable patients (2 days apart: 0.91; 7 days apart: 0.71, 0.74). RS-Total scores correlated significantly with the following criterion variables (Spearman's rho; p < 0.01, all comparisons listed here): FEV1% predicted (-0.19, -0.14, -0.15); St. George's Respiratory Questionnaire (SGRQ) (0.65, 0.52, 0.51); Breathlessness, Cough, and Sputum Scale (BCSS) (0.89, 0.89); modified Medical Research Council dyspnoea scale (mMRC) (0.40); rescue medication use (0.43, 0.42); Functional Performance Inventory Short-Form (FPI-SF) (0.43); 6-minute walk distance (6-MWT) (-0.30, -0.14) and incremental shuttle walk (ISWT) (-0.18) tests. Correlations between these variables and RS-Breathlessness, RS-Cough and Sputum, RS-Chest Symptoms scores supported subscale validity. RS-Total, RS-Breathlessness, and RS-Chest Symptoms differentiated mMRC levels of breathlessness severity (p < 0.0001). RS-Total and domain scores differentiated subjects with no rescue medication use and 3 or more puffs (p < 0.0001). Sensitivity to changes in health status (SGRQ), symptoms (BCSS), and exercise capacity (6MWT, ISWT) were also shown and responder definitions using criterion- and distribution-based methods are proposed. CONCLUSIONS: Results suggest the E-RS is a reliable, valid, and responsive measure of respiratory symptoms of COPD suitable for use in natural history studies and clinical trials. TRIAL REGISTRATION: MPEX: NCT00739648 ; AZ1: NCT00949975 ; AZ 2: NCT01023516.
Authors: N K Leidy; C C Sexton; P W Jones; S M Notte; B U Monz; L Nelsen; M Goldman; L T Murray; S Sethi Journal: Thorax Date: 2014-03-04 Impact factor: 9.139
Authors: Jamuna K Krishnan; Kayley M Ancy; Clara Oromendia; Katherine L Hoffman; Imaani Easthausen; Nancy K Leidy; MeiLan K Han; Russell P Bowler; Stephanie A Christenson; David J Couper; Gerard J Criner; Jeffrey L Curtis; Mark T Dransfield; Nadia N Hansel; Anand S Iyer; Robert Paine Iii; Stephen P Peters; Jadwiga A Wedzicha; Prescott G Woodruff; Karla V Ballman; Fernando J Martinez Journal: Chronic Obstr Pulm Dis Date: 2022-04-29
Authors: Stefan M Frent; Kenneth R Chapman; Michael Larbig; Alexander Mackay; Robert Fogel; Florian S Gutzwiller; Steven Shen; Francesco Patalano; Donald Banerji; Konstantinos Kostikas; Jadwiga A Wedzicha Journal: Am J Respir Crit Care Med Date: 2019-01-01 Impact factor: 21.405
Authors: Claus F Vogelmeier; Ian P Naya; François Maltais; Leif Bjermer; Edward M Kerwin; Lee Tombs; Paul W Jones; Chris Compton; David A Lipson; Isabelle H Boucot Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-05-03
Authors: Eric D Bateman; Kenneth R Chapman; Dave Singh; Anthony D D'Urzo; Eduard Molins; Anne Leselbaum; Esther Garcia Gil Journal: Respir Res Date: 2015-08-02